Inventiva Aktie
| 2,31EUR | -0,05EUR | -1,91% |
WKN DE: A2DLV9 / ISIN: FR0013233012
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 70,68 |
| BVF Partners LP | 9,03 |
| Invus Public Equities Advisors LLC | 8,25 |
| Frédéric Cren, MBA | 6,45 |
| NEA Management Co. LLC | 6,40 |
| Qatar Investment Authority (Investment Management) | 5,92 |
| Sofinnova Partners SAS | 5,82 |
| Andera Partners SCA | 5,75 |
| Perceptive Advisors LLC | 5,20 |
| Pierre Broqua, PhD | 4,46 |
| Yiheng Capital Management LP | 4,42 |
| Polar Capital Funds Plc - Biotechnology Fund | 0,53 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 88 | 94 | 105 | 113 | 123 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,08 | 0,00 | 0,04 | 0,11 | 0,14 |
Bilanz (in Mio. EUR) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 49 | 132 | 115 | 106 | 48 |
| Summe Anlagevermögen | 8 | 6 | 6 | 10 | 21 |
| Summe Aktiva | 57 | 138 | 121 | 116 | 69 |
Bilanz (in Mio. EUR) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 0 | 10 | 10 | 35 | 37 |
| Summe Fremdkapital | 16 | 28 | 33 | 71 | 102 |
| Summe Eigenkapital | 41 | 110 | 88 | 45 | -32 |
| Summe Passiva | 57 | 138 | 121 | 116 | 69 |
Adresse
| 50, rue de Dijon, 21121 Daix | |
| Telefon | +33 (3) 80-44-75-00 |
| Internet | http://www.inventivapharma.com |
Management
|
Alice Roudot-Ketelers
Chief Operating Officer |
|
Annick Schwebig
Independent Director |
|
Chris Buyse
Independent Director |
|
David Nikodem
Vice President-US Operations |
|
Eric Marie Albert Duranson
General Counsel |
|
Frédéric Cren
Chairman & Chief Executive Officer |
|
G. Andre Turenne
Independent Director |
|
Heinz Christoph Mäusli
Independent Director |
|
Jean Volatier
Chief Financial Officer |
|
Kristina Meyer
EVP-Business Development & Alliance Management |
|
Martine Zimmermann
Independent Director |
|
Michael P. Cooreman
Chief Medical Officer |
|
Nathalie Harroy
Head-Human Resources |
|
Pascaline Clerc
Executive VP-Strategy & Corporate Affairs |
|
Pierre Broqua
Director, Chief Scientific Officer & Deputy CEO |
|
Xiao Qin Lu
Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
